End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
60.88 CNY | -0.03% | +1.52% | +22.42% |
04-19 | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-25 | CR Sanjiu's 2023 Profit Climbs 16.5%, Revenue Jumps 37% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+22.42% | 8.33B | B- | ||
+32.36% | 698B | C+ | ||
+26.51% | 568B | B | ||
-4.40% | 358B | C+ | ||
+19.46% | 328B | B- | ||
+3.50% | 283B | C+ | ||
+16.34% | 238B | B+ | ||
+6.68% | 203B | B- | ||
-9.08% | 198B | A+ | ||
+8.62% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000999 Stock
- Ratings China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.